Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid--including a recent phase 3 trial of donanemab published in JAMA--and reviews considerations for their use in patients with Alzheimer disease.
Related Content:
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
ja.ma/45fl0b5
Donanemab in Early Symptomatic Alzheimer Disease
ja.ma/3DN6YBQ
Podcast was originally published on August 3, 2023.
edhub.ama-assn...
---------------------------------------------------------------------------------
Follow JAMA Clinical Reviews on:
TH-cam: • JAMA Clinical Reviews
Apple Podcasts: podcasts.apple...
Spotify: open.spotify.c...
Pocket Casts: pca.st/3ghw
Your podcast app of choice: pod.link/10274...
Website: jamanetwork.co...
---------------------------------------------------------------------------------
For more from JAMA
• www.jama.com
• / jamajournal
• / jama_current
• / jamanetwork
Follow the JAMA Network
• www.jamanetwor...
• www.jamanetwork...
• / jamanetwork
• / jamanetwork
• / jamanetwork
• / jamanetwork

[@JAMANetwork]

Click ja.ma/45fl0b5 to read "Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease" in JAMA.
Click ja.ma/3DN6YBQ to read "Donanemab in Early Symptomatic Alzheimer Disease" in JAMA.